Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Guillain-Barré Syndrome & Drugs/Treatments

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Immunomodulatory treatments, including intravenous immunoglobulins (IVIg) and plasma exchange (PE), have long been the first-line therapies for Guillain-Barré Syndrome. Depending on Guillain-Barré Syndrome subtype and severity at initial presentation, the efficacy of IVIg and PE can be variable.
Liu et al. 2024b Expert Opinion on Therapeutic Targets 28(3): 131–143

References (Sources)

Emerging treatment landscape for Guillain-Barré Syndrome (GBS): what’s new?
Sprenger-Svačina et al. 2024 Expert Opinion on Investigational Drugs 33(9): 881-886
Guillain–Barré syndrome: immunopathogenesis and therapeutic targets
Liu et al. 2024b Expert Opinion on Therapeutic Targets 28(3): 131–143
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Guillain-Barré Syndrome & Drugs/Treatments

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat